agilon health inc header image

agilon health inc

AGL

Equity

ISIN null / Valor 110653729

New York Stock Exchange, Inc (2025-11-21)
USD 0.62+19.0%

agilon health inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Agilon Health Inc. operates as a healthcare company that focuses on transforming the primary care model for senior patients through its Medicare-centric Total Care Model. This innovative approach leverages a unified operating platform that integrates people, processes, and technology to assist physician partners in identifying care gaps, enhancing practice growth, and improving patient outcomes. Unlike companies that aim to own or directly manage physician practices, Agilon positions itself as a collaborative partner, investing 100% of the capital in joint ventures with independent primary-care and multispecialty practices. These partnerships are designed to maintain the autonomy of physicians while enabling them to manage global risk more effectively. Agilon's model emphasizes the importance of the physician-patient relationship and supports the long-term financial sustainability of practices. The company has established strategic relationships with leading national and regional health plans, facilitating a focus on delivering consistent, high-quality care and managing overall health costs efficiently. Through its approach, Agilon aims to empower physicians to deliver superior care to their communities while navigating the complexities of the healthcare system.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (08.10.2025):

agilon health inc reported its financial results for the first quarter of 2025, showcasing a total revenue of $1.53 billion. Despite a 4% decrease in revenue compared to the same period last year, the company achieved a net income of $12 million, reversing a net loss from the previous year. Membership on the agilon platform saw a slight decline, while the company reaffirmed its full-year earnings guidance.

Total Revenue

In the first quarter of 2025, agilon health inc generated total revenues of $1.53 billion, marking a 4% decrease from $1.60 billion in the first quarter of 2024. The decline was primarily due to market exits, although growth in new markets and existing geographies helped offset some of the impact.

Membership Numbers

As of March 31, 2025, agilon health inc had a total of 605,000 members on its platform, including 491,000 Medicare Advantage members and 114,000 ACO REACH model beneficiaries. This represents a 7% decrease in total members compared to the first quarter of 2024, reflecting previously disclosed market exits.

Profitability

The company reported a gross profit of $51 million for the first quarter of 2025, down from $75 million in the same period last year. However, agilon health inc achieved a net income of $12 million, improving from a net loss of $6 million in the first quarter of 2024.

Medical Margin and Adjusted EBITDA

The medical margin for Q1 2025 was $128 million, a 19% decrease from $157 million in Q1 2024. Adjusted EBITDA also declined to $21 million from $29 million year-over-year. These changes were influenced by a negative net impact from prior year claims and other operational factors.

Full-Year Guidance

agilon health inc reaffirmed its full-year 2025 earnings guidance, anticipating continued focus on strategic growth priorities and investments in technology and clinical programs to enhance value for partners, members, and shareholders.

Summarized from source with an LLMView Source

Key figures

-65.1%1Y
-96.1%3Y
%5Y

Performance

126%1Y
92.8%3Y
83.1%5Y

Volatility

Market cap

258 M

Market cap (USD)

Daily traded volume (Shares)

22,326,991

Daily traded volume (Shares)

1 day high/low

1.96 / 1.835

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Edwards Lifesciences Corp
Edwards Lifesciences Corp Edwards Lifesciences Corp Valor: 1065343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.24%USD 85.13
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.18%SEK 342.20